<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240819204435&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240819204435&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 20 Aug 2024 00:44:36 +0000</lastbuilddate>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Correction to: Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159229/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e197. doi: 10.1161/CIR.0000000000001275. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159229/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39159229</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001275>10.1161/CIR.0000000000001275</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159229</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39159229</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001275</dc:identifier>
</item>
<item>
<title>Correction to: Past, Present, and Future of CTA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e199. doi: 10.1161/CIR.0000000000001283. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39159228</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001283>10.1161/CIR.0000000000001283</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159228</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Past, Present, and Future of CTA</dc:title>
<dc:identifier>pmid:39159228</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001283</dc:identifier>
</item>
<item>
<title>Correction to: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159227/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e198. doi: 10.1161/CIR.0000000000001277. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159227/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39159227</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001277>10.1161/CIR.0000000000001277</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159227</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:39159227</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001277</dc:identifier>
</item>
<item>
<title>Does PPG, the Other Dimension to FFR, Better Predict Post-PCI Results?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159226/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):598-599. doi: 10.1161/CIRCULATIONAHA.124.070439. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159226/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39159226</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070439>10.1161/CIRCULATIONAHA.124.070439</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159226</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Morton J Kern</dc:creator>
<dc:creator>Arnold H Seto</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Does PPG, the Other Dimension to FFR, Better Predict Post-PCI Results?</dc:title>
<dc:identifier>pmid:39159226</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070439</dc:identifier>
</item>
<item>
<title>Congenital Heart Surgery: In Rapid Evolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159225/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):583-585. doi: 10.1161/CIRCULATIONAHA.124.068655. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159225/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39159225</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068655>10.1161/CIRCULATIONAHA.124.068655</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159225</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Pedro J Del Nido</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Congenital Heart Surgery: In Rapid Evolution</dc:title>
<dc:identifier>pmid:39159225</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068655</dc:identifier>
</item>
<item>
<title>Diagnosis of Brugada Syndrome With a Sodium-Channel-Blocker Test: Who Should Be Tested? Who Should Not?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>Intravenous infusion of sodium-channel blockers (SCB) with either ajmaline, flecainide, procainamide, or pilsicainide to unmask the ECG of Brugada syndrome is the drug challenge most commonly used for diagnostic purposes when investigating cases possibly related to inherited arrhythmia syndromes. For a patient undergoing an SCB challenge, the impact of a positive result goes well beyond its diagnostic implications. It is, therefore, appropriate to question who should undergo a SCB test to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):642-650. doi: 10.1161/CIRCULATIONAHA.124.069138. Epub 2024 Aug 19.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Intravenous infusion of sodium-channel blockers (SCB) with either ajmaline, flecainide, procainamide, or pilsicainide to unmask the ECG of Brugada syndrome is the drug challenge most commonly used for diagnostic purposes when investigating cases possibly related to inherited arrhythmia syndromes. For a patient undergoing an SCB challenge, the impact of a positive result goes well beyond its diagnostic implications. It is, therefore, appropriate to question who should undergo a SCB test to diagnose or exclude Brugada syndrome and, perhaps more importantly, who should not. We present a critical review of the benefits and drawbacks of the SCB challenge when performed in cardiac arrest survivors, patients presenting with syncope, family members of probands with confirmed Brugada syndrome, and asymptomatic patients with suspicious ECG.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39159224</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069138>10.1161/CIRCULATIONAHA.124.069138</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159224</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sami Viskin</dc:creator>
<dc:creator>Ehud Chorin</dc:creator>
<dc:creator>Raphael Rosso</dc:creator>
<dc:creator>Ahmad S Amin</dc:creator>
<dc:creator>Arthur A Wilde</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Diagnosis of Brugada Syndrome With a Sodium-Channel-Blocker Test: Who Should Be Tested? Who Should Not?</dc:title>
<dc:identifier>pmid:39159224</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069138</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159223/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):651-656. doi: 10.1161/CIRCULATIONAHA.124.071487. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159223/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39159223</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071487>10.1161/CIRCULATIONAHA.124.071487</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159223</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:39159223</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071487</dc:identifier>
</item>
<item>
<title>Letter by Zhang et al Regarding Article, "Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159222/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e181-e182. doi: 10.1161/CIRCULATIONAHA.124.069623. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159222/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39159222</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069623>10.1161/CIRCULATIONAHA.124.069623</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159222</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhipeng Zhang</dc:creator>
<dc:creator>Kai Liu</dc:creator>
<dc:creator>Xiaoping Chen</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Zhang et al Regarding Article, "Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program"</dc:title>
<dc:identifier>pmid:39159222</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069623</dc:identifier>
</item>
<item>
<title>Junctophilin-2 Regulates Mitochondrial Metabolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159221/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):657-660. doi: 10.1161/CIRCULATIONAHA.123.064343. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159221/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39159221</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064343>10.1161/CIRCULATIONAHA.123.064343</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159221</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sasha Z Prisco</dc:creator>
<dc:creator>Lynn M Hartweck</dc:creator>
<dc:creator>Felipe Kazmirczak</dc:creator>
<dc:creator>Jenna B Mendelson</dc:creator>
<dc:creator>Stephanie L Deng</dc:creator>
<dc:creator>Madelyn Blake</dc:creator>
<dc:creator>Satadru K Lahiri</dc:creator>
<dc:creator>Xander H T Wehrens</dc:creator>
<dc:creator>Kurt W Prins</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Junctophilin-2 Regulates Mitochondrial Metabolism</dc:title>
<dc:identifier>pmid:39159221</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064343</dc:identifier>
</item>
<item>
<title>More questions than answers after NOTION-2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158500/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae527. doi: 10.1093/eurheartj/ehae527. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158500/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39158500</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae527>10.1093/eurheartj/ehae527</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158500</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Victor Dayan</dc:creator>
<dc:creator>Sanjay Kaul</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>More questions than answers after NOTION-2</dc:title>
<dc:identifier>pmid:39158500</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae527</dc:identifier>
</item>
<item>
<title>Underpowered trials: redundant or useful as a canary in the coal mine?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158494/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae528. doi: 10.1093/eurheartj/ehae528. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158494/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39158494</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae528>10.1093/eurheartj/ehae528</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158494</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Troels Højsgaard Jørgensen</dc:creator>
<dc:creator>Hans Gustav Hørsted Thyregod</dc:creator>
<dc:creator>Ole De Backer</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Underpowered trials: redundant or useful as a canary in the coal mine?</dc:title>
<dc:identifier>pmid:39158494</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae528</dc:identifier>
</item>
<item>
<title>Loop diuretics in cardiovascular disease: friend or foe?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158480/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae483. doi: 10.1093/eurheartj/ehae483. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39158480</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae483>10.1093/eurheartj/ehae483</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158480</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Annika Rosengren</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Loop diuretics in cardiovascular disease: friend or foe?</dc:title>
<dc:identifier>pmid:39158480</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae483</dc:identifier>
</item>
<item>
<title>Multi-stakeholder workshop on reducing population-wide dietary sodium intake in Nigeria</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae461. doi: 10.1093/eurheartj/ehae461. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39158473</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae461>10.1093/eurheartj/ehae461</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158473</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Chisom Obiezu-Umeh</dc:creator>
<dc:creator>Mark D Huffman</dc:creator>
<dc:creator>Dike Ojji</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Multi-stakeholder workshop on reducing population-wide dietary sodium intake in Nigeria</dc:title>
<dc:identifier>pmid:39158473</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae461</dc:identifier>
</item>
<item>
<title>Artificial intelligence in cardiovascular medicine: clinical applications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158472/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>Clinical medicine requires the integration of various forms of patient data including demographics, symptom characteristics, electrocardiogram findings, laboratory values, biomarker levels, and imaging studies. Decision-making on the optimal management should be based on a high probability that the envisaged treatment is appropriate, provides benefit, and bears no or little potential harm. To that end, personalized risk-benefit considerations should guide the management of individual patients to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae465. doi: 10.1093/eurheartj/ehae465. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Clinical medicine requires the integration of various forms of patient data including demographics, symptom characteristics, electrocardiogram findings, laboratory values, biomarker levels, and imaging studies. Decision-making on the optimal management should be based on a high probability that the envisaged treatment is appropriate, provides benefit, and bears no or little potential harm. To that end, personalized risk-benefit considerations should guide the management of individual patients to achieve optimal results. These basic clinical tasks have become more and more challenging with the massively growing data now available; artificial intelligence and machine learning (AI/ML) can provide assistance for clinicians by obtaining and comprehensively preparing the history of patients, analysing face and voice and other clinical features, by integrating laboratory results, biomarkers, and imaging. Furthermore, AI/ML can provide a comprehensive risk assessment as a basis of optimal acute and chronic care. The clinical usefulness of AI/ML algorithms should be carefully assessed, validated with confirmation datasets before clinical use, and repeatedly re-evaluated as patient phenotypes change. This review provides an overview of the current data revolution that has changed and will continue to change the face of clinical medicine radically, if properly used, to the benefit of physicians and patients alike.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158472/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39158472</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae465>10.1093/eurheartj/ehae465</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158472</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:creator>Florian A Wenzl</dc:creator>
<dc:creator>Fabrizio D'Ascenzo</dc:creator>
<dc:creator>Paul A Friedman</dc:creator>
<dc:creator>Charalambos Antoniades</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence in cardiovascular medicine: clinical applications</dc:title>
<dc:identifier>pmid:39158472</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae465</dc:identifier>
</item>
<item>
<title>The European examination in core cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158467/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae453. doi: 10.1093/eurheartj/ehae453. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158467/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39158467</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae453>10.1093/eurheartj/ehae453</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158467</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Chris Plummer</dc:creator>
<dc:creator>Susanna Price</dc:creator>
<dc:creator>Lampros Michalis</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The European examination in core cardiology</dc:title>
<dc:identifier>pmid:39158467</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae453</dc:identifier>
</item>
<item>
<title>Antisense Oligonucleotide Therapy for Calmodulinopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39155863/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results provide proof of concept that ASOs targeting individual calmodulin genes are potentially effective and safe therapies for calmodulinopathies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 19. doi: 10.1161/CIRCULATIONAHA.123.068111. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Calmodulinopathies are rare inherited arrhythmia syndromes caused by dominant heterozygous variants in <i>CALM1</i>, <i>CALM2</i>, or <i>CALM3</i>, which each encode the identical CaM (calmodulin) protein. We hypothesized that antisense oligonucleotide (ASO)-mediated depletion of an affected calmodulin gene would ameliorate disease manifestations, whereas the other 2 calmodulin genes would preserve CaM level and function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We tested this hypothesis using human induced pluripotent stem cell-derived cardiomyocyte and mouse models of <i>CALM1</i> pathogenic variants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Human <i>CALM1</i><sup><i>F142L/+</i></sup> induced pluripotent stem cell-derived cardiomyocytes exhibited prolonged action potentials, modeling congenital long QT syndrome. CALM1 knockout or CALM1-depleting ASOs did not alter CaM protein level and normalized repolarization duration of <i>CALM1</i><sup><i>F142L/+</i></sup> induced pluripotent stem cell-derived cardiomyocytes. Similarly, an ASO targeting murine <i>Calm1</i> depleted <i>Calm1</i> transcript without affecting CaM protein level. This ASO alleviated drug-induced bidirectional ventricular tachycardia in <i>Calm</i><sup><i>N98S/+</i></sup> mice without a deleterious effect on cardiac electrical or contractile function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results provide proof of concept that ASOs targeting individual calmodulin genes are potentially effective and safe therapies for calmodulinopathies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39155863/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39155863</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068111>10.1161/CIRCULATIONAHA.123.068111</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39155863</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Raul H Bortolin</dc:creator>
<dc:creator>Farina Nawar</dc:creator>
<dc:creator>Chaehyoung Park</dc:creator>
<dc:creator>Michael A Trembley</dc:creator>
<dc:creator>Maksymilian Prondzynski</dc:creator>
<dc:creator>Mason E Sweat</dc:creator>
<dc:creator>Peizhe Wang</dc:creator>
<dc:creator>Jiehui Chen</dc:creator>
<dc:creator>Fujian Lu</dc:creator>
<dc:creator>Carter Liou</dc:creator>
<dc:creator>Paul Berkson</dc:creator>
<dc:creator>Erin M Keating</dc:creator>
<dc:creator>Daisuke Yoshinaga</dc:creator>
<dc:creator>Nikoleta Pavlaki</dc:creator>
<dc:creator>Thomas Samenuk</dc:creator>
<dc:creator>Cecilia B Cavazzoni</dc:creator>
<dc:creator>Peter T Sage</dc:creator>
<dc:creator>Qing Ma</dc:creator>
<dc:creator>Robert D Whitehill</dc:creator>
<dc:creator>Dominic J Abrams</dc:creator>
<dc:creator>Chrystalle K Carreon</dc:creator>
<dc:creator>Juan Putra</dc:creator>
<dc:creator>Sanda Alexandrescu</dc:creator>
<dc:creator>Shuai Guo</dc:creator>
<dc:creator>Wen-Chin Tsai</dc:creator>
<dc:creator>Michael Rubart</dc:creator>
<dc:creator>Dieter Kubli</dc:creator>
<dc:creator>Adam E Mullick</dc:creator>
<dc:creator>Vassilios J Bezzerides</dc:creator>
<dc:creator>William T Pu</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Antisense Oligonucleotide Therapy for Calmodulinopathy</dc:title>
<dc:identifier>pmid:39155863</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068111</dc:identifier>
</item>
<item>
<title>Cardiovascular disease assessment and management in liver transplantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39152050/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>The prevalence and mortality related to end-stage liver disease (ESLD) continue to rise globally. Liver transplant (LT) recipients continue to be older and have inherently more comorbidities. Among these, cardiac disease is one of the three main causes of morbidity and mortality after LT. Several reasons exist including the high prevalence of associated risk factors, which can also be attributed to the rise in the proportion of patients undergoing LT for metabolic dysfunction-associated...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 17:ehae502. doi: 10.1093/eurheartj/ehae502. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The prevalence and mortality related to end-stage liver disease (ESLD) continue to rise globally. Liver transplant (LT) recipients continue to be older and have inherently more comorbidities. Among these, cardiac disease is one of the three main causes of morbidity and mortality after LT. Several reasons exist including the high prevalence of associated risk factors, which can also be attributed to the rise in the proportion of patients undergoing LT for metabolic dysfunction-associated steatohepatitis (MASH). Additionally, as people age, the prevalence of now treatable cardiac conditions, including coronary artery disease (CAD), cardiomyopathies, significant valvular heart disease, pulmonary hypertension, and arrhythmias rises, making the need to treat these conditions critical to optimize outcomes. There is an emerging body of literature regarding CAD screening in patients with ESLD, however, there is a paucity of strong evidence to support the guidance regarding the management of cardiac conditions in the pre-LT and perioperative settings. This has resulted in significant variations in assessment strategies and clinical management of cardiac disease in LT candidates between transplant centres, which impacts LT candidacy based on a transplant centre's risk tolerance and comfort level for caring for patients with concomitant cardiac disease. Performing a comprehensive assessment and understanding the potential approaches to the management of ESLD patients with cardiac conditions may increase the acceptance of patients, who appear too complex, but rather require extra evaluation and may be reasonable candidates for LT. The unique physiology of ESLD can profoundly influence preoperative assessment, perioperative management, and outcomes associated with underlying cardiac pathology, and requires a thoughtful multidisciplinary approach. The strategies proposed in this manuscript attempt to review the latest expert experience and opinions and provide guidance to practicing clinicians who assess and treat patients being considered for LT. These topics also highlight the gaps that exist in the comprehensive care of LT patients and the need for future investigations in this field.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39152050/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39152050</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae502>10.1093/eurheartj/ehae502</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39152050</guid>
<pubDate>Fri, 16 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew E Harinstein</dc:creator>
<dc:creator>Caterina Gandolfo</dc:creator>
<dc:creator>Salvatore Gruttadauria</dc:creator>
<dc:creator>Caterina Accardo</dc:creator>
<dc:creator>Gonzalo Crespo</dc:creator>
<dc:creator>Lisa B VanWagner</dc:creator>
<dc:creator>Abhinav Humar</dc:creator>
<dc:date>2024-08-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular disease assessment and management in liver transplantation</dc:title>
<dc:identifier>pmid:39152050</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae502</dc:identifier>
</item>
<item>
<title>Expanding knowledge in atrial fibrillation, blood pressure treatment, and management of coronary and peripheral artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39150995/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 16;45(31):2795-2799. doi: 10.1093/eurheartj/ehae503.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39150995/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39150995</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae503>10.1093/eurheartj/ehae503</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39150995</guid>
<pubDate>Fri, 16 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-08-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Expanding knowledge in atrial fibrillation, blood pressure treatment, and management of coronary and peripheral artery disease</dc:title>
<dc:identifier>pmid:39150995</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae503</dc:identifier>
</item>
<item>
<title>Intra-atrial re-entries in a 'doughnut' atrium</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39150945/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 16:ehae514. doi: 10.1093/eurheartj/ehae514. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39150945/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39150945</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae514>10.1093/eurheartj/ehae514</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39150945</guid>
<pubDate>Fri, 16 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Pietro Paolo Tamborrino</dc:creator>
<dc:creator>Sarah Ghonim</dc:creator>
<dc:creator>Sabine Ernst</dc:creator>
<dc:date>2024-08-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intra-atrial re-entries in a 'doughnut' atrium</dc:title>
<dc:identifier>pmid:39150945</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae514</dc:identifier>
</item>
<item>
<title>The humanized platelet glycoprotein VI Fab inhibitor EMA601 protects from arterial thrombosis and ischaemic stroke in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39150906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: EMA601 is a conceptually novel and promising anti-platelet agent to efficiently prevent or treat arterial thrombosis and thrombo-inflammatory pathologies in humans at risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 16:ehae482. doi: 10.1093/eurheartj/ehae482. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Glycoprotein VI (GPVI) is a platelet collagen/fibrin(ogen) receptor and an emerging pharmacological target for the treatment of thrombotic and thrombo-inflammatory diseases, notably ischaemic stroke. A first anti-human GPVI (hGPVI) antibody Fab-fragment (ACT017/glenzocimab, KD: 4.1 nM) recently passed a clinical phase 1b/2a study in patients with acute ischaemic stroke and was found to be well tolerated, safe, and potentially beneficial. In this study, a novel humanized anti-GPVI antibody Fab-fragment (EMA601; KD: 0.195 nM) was developed that inhibits hGPVI function with very high potency in vitro and in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Fab-fragments of the mouse anti-hGPVI IgG Emf6.1 were tested for functional GPVI inhibition in human platelets and in hGPVI expressing (hGP6tg/tg) mouse platelets. The in vivo effect of Emf6.1Fab was assessed in a tail bleeding assay, an arterial thrombosis model and the transient middle cerebral artery occlusion (tMCAO) model of ischaemic stroke. Using complementary-determining region grafting, a humanized version of Emf6.1Fab (EMA601) was generated. Emf6.1Fab/EMA601 interaction with hGPVI was mapped in array format and kinetics and quantified by bio-layer interferometry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Emf6.1Fab (KD: 0.427 nM) blocked GPVI function in human and hGP6tg/tg mouse platelets in multiple assays in vitro at concentrations ≥5 µg/mL. Emf6.1Fab (4 mg/kg)-treated hGP6tg/tg mice showed potent hGPVI inhibition ex vivo and were profoundly protected from arterial thrombosis as well as from cerebral infarct growth after tMCAO, whereas tail-bleeding times remained unaffected. Emf6.1Fab binds to a so far undescribed membrane proximal epitope in GPVI. The humanized variant EMA601 displayed further increased affinity for hGPVI (KD: 0.195 nM) and fully inhibited the receptor at 0.5 µg/mL, corresponding to a >;50-fold potency compared with ACT017.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: EMA601 is a conceptually novel and promising anti-platelet agent to efficiently prevent or treat arterial thrombosis and thrombo-inflammatory pathologies in humans at risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39150906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39150906</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae482>10.1093/eurheartj/ehae482</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39150906</guid>
<pubDate>Fri, 16 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Stefano Navarro</dc:creator>
<dc:creator>Ivan Talucci</dc:creator>
<dc:creator>Vanessa Göb</dc:creator>
<dc:creator>Stefanie Hartmann</dc:creator>
<dc:creator>Sarah Beck</dc:creator>
<dc:creator>Valerie Orth</dc:creator>
<dc:creator>Guido Stoll</dc:creator>
<dc:creator>Hans M Maric</dc:creator>
<dc:creator>David Stegner</dc:creator>
<dc:creator>Bernhard Nieswandt</dc:creator>
<dc:date>2024-08-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The humanized platelet glycoprotein VI Fab inhibitor EMA601 protects from arterial thrombosis and ischaemic stroke in mice</dc:title>
<dc:identifier>pmid:39150906</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae482</dc:identifier>
</item>
<item>
<title>Leveraging genetic data to improve the care of patients with thoracic aortic dilation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39150456/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240819204435&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 16:ehae499. doi: 10.1093/eurheartj/ehae499. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39150456/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240819204435&v=2.18.0.post9+e462414">39150456</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae499>10.1093/eurheartj/ehae499</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39150456</guid>
<pubDate>Fri, 16 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>John DePaolo</dc:creator>
<dc:creator>David Y Zhang</dc:creator>
<dc:creator>Scott M Damrauer</dc:creator>
<dc:date>2024-08-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leveraging genetic data to improve the care of patients with thoracic aortic dilation</dc:title>
<dc:identifier>pmid:39150456</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae499</dc:identifier>
</item>





























</channel>
</rss>